Barbara Sleight

2.4k citations
23 papers · 1.6k · 2 hit papers · h-index 10

Impact in

Papers in

Barbara Sleight

23 papers receiving 1.6k citations

Barbara Sleight's Hit Papers

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study 2019 · 242 citations
2420+3+6Years since publication250500750

Peers

Barbara Sleight
Comparison fields: 5 of 67
  • Hematology 585
  • Public Health, Environmental and Occupational Health 909
  • Oncology 836
  • Pathology and Forensic Medicine 227
  • Pediatrics, Perinatology and Child Health 195
Replace Richard Champlin with:
Richard Champlin United States
Taiga Nishihori United States
ER van Wering Netherlands
Thibaut Leguay France
Musa Yılmaz United States
Paul Cannell Australia
Wilhelm Woessmann Germany
F. R. Appelbaum United States
Deok‐Hwan Yang South Korea
Akitoshi Kinoshita Japan
Barbara Sleight relative to Richard Champlin United States Richard Champlin's profile →
Citations per field
00.5×10×15×20×
Richard Champlin · 1×
Citations per year

Countries citing papers authored by Barbara Sleight

Since Specialization
Citations

This map shows the geographic impact of Barbara Sleight's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Sleight with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Sleight more than expected).

Fields of papers citing papers by Barbara Sleight

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Sleight. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Sleight. The network helps show where Barbara Sleight may publish in the future.

Co-authors

The 25 scholars most cited alongside Barbara Sleight, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barbara Sleight Line = papers co-authored together Barbara Sleight links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 23 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hit paper breakdown →
2016951
2
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
Hit paper breakdown →
2019242
3 2017155
4 201846
5 201940
6 202133
7 199823
8 201115
9 201213
10 201913
11 20199
12 19998
13 20197
14 20166
15 20175
16 20185
17 20185
18 20164
19 20193
20 20162

About Barbara Sleight

Barbara Sleight is a scholar working on Public Health, Environmental and Occupational Health, Oncology, Hematology, Genetics and Molecular Biology, having authored 23 papers that have together received 1.6k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (15 papers), CAR-T cell therapy research (8 papers), Chronic Myeloid Leukemia Treatments (5 papers), Chronic Lymphocytic Leukemia Research (4 papers), Acute Myeloid Leukemia Research (3 papers), Hedgehog Signaling Pathway Studies (2 papers), HER2/EGFR in Cancer Research (2 papers) and Pharmaceutical studies and practices (2 papers). The work is most often cited by research in Hematology (585 citations), Public Health, Environmental and Occupational Health (909 citations), Oncology (836 citations), Pathology and Forensic Medicine (227 citations) and Pediatrics, Perinatology and Child Health (195 citations). Barbara Sleight has collaborated with scholars based in United States, Germany and Italy. Frequent co-authors include Erik Vandendries, Anjali S. Advani, Hagop M. Kantarjian, Matthias Stelljes, Daniel J. DeAngelo, Susan O’Brien, Wendy Stock, Michaela Liedtke, Nicola Gökbuget and Tao Wang. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, Clinical Cancer Research and Future Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact